Reply  by Fonarow, Gregg C. et al.
C
o
P
W
e
d
a
d
b
m
a
l
w
v
m
t
a
(
u
e
s
w
t
a
m
n
p
d
e
d
h
U
t
a
o
c
p
c
m
i
*
J
N
*
J
A
Journal of the American College of Cardiology Vol. 52, No. 24, 2008
© 2008 by the American College of Cardiology Foundation ISSN 0735-1097/08/$34.00
Published by Elsevier Inc.CORRESPONDENCELetters to the Editor
1
S
E
R
1
2
3
R
W
i
r
u
A
i
s
b
f
v
A
f
a
m
u
(
p
m
m
a
t
v
e
r
c
r
a
t
c
b
u
i
f
w
F
o
iontinuation or Withdrawal
f Beta-Blocker Therapy in
atients Admitted for Heart Failure
e read with great interest the article by Fonarow et al. (1)
valuating the effect of continuation or withdrawal of beta-blocker
rugs on outcomes in patients hospitalized with heart failure. The
uthors performed an analysis of 2,374 patients admitted with
ecompensated heart failure and concluded that withdrawal of
eta-blocker therapy in these patients was associated with higher
ortality.
There are several baseline characteristics that substantially differ
mong treatment groups. In addition to differences in the preva-
ence of coronary risk factors and coronary artery disease, patients
ho were withdrawn from beta-blocker drugs had lower left
entricular ejection fraction and higher expected post-discharge
ortality risk. The authors performed a propensity score analysis
o adjust for potential treatment selection bias.
Propensity scores represent the conditional probability of being
ssigned to a treatment group given a set of potential confounders
2,3). The bias and variance of the estimated effect of the treatment
nder study depend on the covariates selected for propensity score
stimation. The authors claim that the propensity scores in their
tudy were calculated with the set of all possible covariates that
ere related to the probability of receiving beta-blocker therapy;
he inclusion of all information regarding the factors that might
ffect the selection of the treatment is, in fact, an important
ainstay of propensity score analysis. However, the authors did
ot indicate which variables they used for estimation of the
ropensity scores. Furthermore, the reasons for beta-blocker with-
rawal during hospital stay were not collected; this information is
ssential, because beta-blocker continuation or withdrawal might
epend strongly on the clinical evolution of the patient during
ospital stay, which in turn might be associated with outcome.
nfortunately, the authors also failed to provide information on
he accuracy of the propensity scores for predicting treatment
ssignment, which might be assessed by the area under the receiver
perating characteristic curve of the logistic regression model.
The presence of unmeasured variables that both affect the
hoice of the treatment and the outcome and the generation of
ropensity scores from potentially inaccurate models might pre-
lude an adequate comparison among the different groups, which
ight compromise the validity of the estimated effect of the
ntervention.
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e are grateful to Dr. Bouzas-Mosquera and colleagues for their
nterest in our article (1). They raise several important issues and
equest additional details regarding the propensity score analysis
sed in this study to adjust for potential treatment selection bias.
s noted in the article, although most variables of prognostic
mportance (e.g., age, systolic blood pressure, heart rate, creatinine,
odium) were similar between patients in the group continued on
eta-blocker drugs and those withdrawn, left ventricular ejection
raction was lower (2.7 unit absolute difference), and a few other
ariables differed in patients withdrawn from beta-blocker therapy.
lthough withdrawal of beta-blocker drugs was associated with a
ew indicators of more severe heart failure, it remained significantly
nd independently associated with increased mortality after adjust-
ent for multiple covariates and propensity score. The variables
sed for the propensity score are posted at the OPTIMIZE-HF
Organized Program To Initiate life-saving treatMent In hospitaliZEd
atients with Heart Failure) website (2). We applied accepted
odeling techniques to obtain the best fit for each variable in the
odel. The c-index of the propensity scores for the treatment
ssignment in this study was 0.649. Weitzen et al. (3) have shown
hat the c-index is not a good measure of the likelihood of omitted
ariables. One way to view this is that the best case scenario for
stimating treatment differences would be under the assumption of
andomization. A propensity score for this situation should have a
-index of 0.50, because no factor should be associated with
eceiving the randomized therapy. We have performed a sensitivity
nalysis (4). This indicates that an unknown covariate would need
o have an odds ratio in the model of approximately 5 before we
ould obtain the opposite interpretation for the use of withdrawing
eta-blocker drugs on post-discharge mortality. It seems fairly
nlikely, although certainly possible, that a factor of such great
mportance was missed. We fully agree that the specific rationale
or beta-blocker continuation and withdrawal during hospital stay
ere not collected, and this might have influenced the findings.
urthermore, despite covariate and propensity score adjustment,
ther measured and unmeasured factors might have influenced
mprovements in clinical outcomes associated with continuation or
ithdrawal of beta-blocker therapy. Nevertheless the findings of
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December 9, 2008:2044–5his OPTIMIZE-HF study are consistent with prior studies and
urrent heart failure guidelines. Routine discontinuation of beta-
locker therapy on hospital admission is neither necessary nor
dvisable, and the majority of patients hospitalized for heart failure
re eligible for beta-blocker therapy to be continued.
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